Citi Upgrades Ultragenyx Pharma (RARE) to Neutral
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Price: $25.32 -3.51%
Rating Summary:
21 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
21 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz upgraded Ultragenyx Pharma (NASDAQ: RARE) from Sell to Neutral with a price target of $54.00 (from $46.00).
For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.
Shares of Ultragenyx Pharma closed at $53.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) PT Raised to $83 at Canaccord
- NetEase.com (NTES) PT Lowered to $143 at Macquarie
- Marti Technologies (MRT) PT Raised to $6 at Benchmark on Stronger Growth, Improved Earnings Visibility
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
